Last updated: September 8, 2026
Deucravacitinib, marketed by Bristol Myers Squibb as Sotyktu, is the first approved selective TYK2 inhibitor for plaque psoriasis. Its commercial profile depends on conversion from biologic therapy, expansion into psoriatic arthritis and immune-mediated diseases, and protection from IL-23 biologics, IL-17 inhibitors, conventional systemic agents, and future TYK2 competitors. Sotyktu generated approximately $250 million in global revenue in 2023, with quarterly sales accelerating during the first half of 2024. Bristol Myers Squibb has identified the product as a major growth asset, with peak-sales expectations of more than $4 billion across potential indications.
What is deucravacitinib and how does Sotyktu work?
Deucravacitinib is an oral, selective inhibitor of tyrosine kinase 2, or TYK2. It binds the regulatory pseudokinase domain of TYK2 rather than the conserved catalytic domain targeted by traditional Janus kinase inhibitors.
This mechanism inhibits signaling mediated by interleukin-12, interleukin-23, and type I interferons. The selectivity is commercially important because it is intended to avoid broader JAK1, JAK2, and JAK3 inhibition associated with certain hematologic, cardiovascular, thrombotic, and malignancy warnings.
The FDA approved Sotyktu on September 9, 2022, for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.[1] The approved dose is 6 mg orally once daily, with or without food.
FDA regulatory status
| Regulatory item |
Status |
| Active ingredient |
Deucravacitinib |
| Brand |
Sotyktu |
| Sponsor |
Bristol-Myers Squibb Company |
| FDA approval |
September 9, 2022 |
| Initial indication |
Moderate-to-severe plaque psoriasis |
| Dosage |
6 mg once daily |
| Administration |
Oral |
| Biologic |
No |
| FDA boxed warning |
None on the U.S. prescribing information as of June 2024 |
| Key safety monitoring |
Infections, tuberculosis, malignancy, rhabdomyolysis, hypersensitivity |
| Major expansion programs |
Psoriatic arthritis, systemic lupus erythematosus, inflammatory bowel disease |
The European Commission authorized Sotyktu for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Approval in additional jurisdictions has expanded the commercial footprint, but U.S. access remains the main driver of the product’s financial value.
How large is the market for deucravacitinib?
The primary market is systemic treatment for moderate-to-severe plaque psoriasis. This market includes oral small molecules, injectable biologics, phototherapy, and older systemic medicines such as methotrexate and cyclosporine.
The commercial opportunity is large because psoriasis is chronic, treatment often continues for years, and biologic use has increased in patients with high disease burden. Sotyktu competes in three segments:
- Established oral systemic therapies, including apremilast.
- High-efficacy biologics, particularly IL-17 and IL-23 inhibitors.
- Emerging oral TYK2 inhibitors.
Sotyktu’s principal commercial differentiation is the combination of oral administration, selective TYK2 inhibition, and clinical efficacy that approaches the performance expected from modern biologic therapy.
Competitive products
| Product |
Company |
Mechanism |
Route |
Commercial relevance |
| Sotyktu |
Bristol Myers Squibb |
Selective TYK2 inhibitor |
Oral |
Direct reference product |
| Otezla |
Amgen |
PDE4 inhibitor |
Oral |
Established oral psoriasis competitor |
| Tremfya |
Johnson & Johnson |
IL-23 inhibitor |
Injectable |
High-efficacy biologic |
| Skyrizi |
AbbVie |
IL-23 inhibitor |
Injectable |
Major psoriasis and IBD product |
| Bimzelx |
UCB |
IL-17A/F inhibitor |
Injectable |
Newer high-efficacy biologic |
| Taltz |
Eli Lilly |
IL-17A inhibitor |
Injectable |
Established biologic |
| Cosentyx |
Novartis |
IL-17A inhibitor |
Injectable |
Broad immunology franchise |
| Rinvoq |
AbbVie |
JAK1 inhibitor |
Oral |
Oral immunology competitor, but not a direct TYK2 product |
| Deucravacitinib follow-ons |
Multiple companies |
Potential TYK2 mechanisms |
Oral |
Future competitive risk |
Sotyktu is most likely to gain share from patients and prescribers seeking an oral alternative to injections. Its main limitation is that biologics have established treatment algorithms, payer contracts, specialist familiarity, and long-term efficacy data.
What is the financial trajectory of Sotyktu?
Sotyktu is in the early commercialization phase. Bristol Myers Squibb reported approximately $250 million in 2023 worldwide sales, compared with a limited contribution in its 2022 launch period.[2] First-quarter 2024 revenue was approximately $111 million, implying an annualized run rate above $440 million before later-quarter prescription growth and international expansion.[3]
| Period |
Approximate Sotyktu revenue |
Commercial interpretation |
| 2022 |
Launch-period revenue |
Initial U.S. launch |
| 2023 |
$250 million |
First full year of commercialization |
| Q1 2024 |
$111 million |
Continued prescription and access expansion |
| 2024 onward |
Not established in the cited disclosures |
Depends on indication expansion and payer uptake |
| Long-term target |
More than $4 billion peak sales potential |
Bristol Myers Squibb strategic objective across indications |
The growth curve is expected to be faster than a conventional psoriasis launch if Sotyktu achieves meaningful use in psoriatic arthritis or systemic lupus erythematosus. Those indications would materially increase the addressable population and reduce dependence on a single dermatology market.
Main revenue drivers
Sotyktu’s revenue trajectory depends on five factors:
- New-to-brand prescriptions from dermatologists.
- Switching from oral apremilast and other systemic agents.
- Use before or instead of injectable biologics.
- Commercial formulary placement and rebate levels.
- Regulatory expansion into rheumatology and other autoimmune diseases.
Net pricing is likely to be lower than list pricing because U.S. specialty drugs are sold through rebates, copay assistance, government discounts, and payer concessions. A large increase in prescription volume could therefore produce a smaller increase in reported net sales.
Revenue exposure to Bristol Myers Squibb
Sotyktu is strategically important because Bristol Myers Squibb faces loss-of-exclusivity pressure across several mature products, including Revlimid and later-stage risks involving Eliquis and Opdivo. The company has identified newer medicines such as Camzyos, Reblozyl, Breyanzi, Augtyro, and Sotyktu as growth assets.
Sotyktu does not yet offset the revenue scale of the company’s largest products. Its value is based on the expected duration of growth and the possibility of expansion beyond psoriasis.
When does deucravacitinib lose exclusivity?
The main U.S. exclusivity barriers are regulatory exclusivity and patents.
The FDA granted Sotyktu new chemical entity exclusivity because deucravacitinib had not previously been approved as an active ingredient in the United States. Five-year NCE exclusivity generally prevents submission of an ANDA or 505(b)(2) application relying on the product’s clinical data until September 2027, subject to statutory exceptions.[4]
The practical generic entry date may be later than 2027 because patent litigation, court decisions, pediatric exclusivity, and the timing of an ANDA approval can extend the effective protection period.
U.S. exclusivity timeline
| Event |
Date or period |
| FDA approval |
September 9, 2022 |
| Five-year NCE exclusivity |
Generally through September 2027 |
| Earliest likely ANDA submission window for Paragraph IV |
Generally after four years, around September 2026 |
| Potential first generic approval |
No earlier than the resolution of NCE and patent barriers |
| Core patent protection |
Expected to extend into the 2030s, subject to Orange Book records and patent-term adjustment |
Bristol Myers Squibb’s principal U.S. protection is based on patents covering the active compound and related pharmaceutical compositions. The commercial value of Sotyktu depends more on composition and formulation protection than on a narrow method-of-use patent because generic manufacturers can seek approval for the same psoriasis indication after regulatory barriers expire.
The FDA Orange Book is the controlling source for listed patents, pediatric exclusivity, patent-term adjustment, and any statutory listing changes.[5]
What patents protect Sotyktu?
Sotyktu’s patent estate is expected to include protection for:
- Deucravacitinib and related chemical compounds.
- Pharmaceutical compositions containing the active ingredient.
- Solid-state or crystalline forms, if separately claimed.
- Dosage forms and oral administration.
- Methods of treating psoriasis and other inflammatory diseases.
- Manufacturing processes and intermediates.
Composition-of-matter protection is normally the strongest layer because it can block products containing the same active molecule regardless of formulation. Formulation and method-of-use patents are less durable if a generic company can design around them or omit protected indications from its label.
Patent strength assessment
| Protection layer |
Likely strength |
Commercial role |
| Active compound |
High |
Primary barrier to substitution |
| Pharmaceutical composition |
Moderate to high |
Supports product protection |
| Specific dosage regimen |
Moderate |
Protects labeled use and dosing |
| Psoriasis method of use |
Moderate |
Important for Orange Book litigation |
| Manufacturing process |
Variable |
Can raise API supply and quality barriers |
| Solid-state form |
Variable |
Relevant if the marketed form is specifically claimed |
The patent estate appears commercially meaningful because the active ingredient is protected beyond the five-year NCE period. A generic entrant would likely need to challenge patents through Paragraph IV certification or wait for expiration.
Which companies are challenging deucravacitinib patents?
No major U.S. generic challenge had materially altered Sotyktu’s commercial position as of June 2024. The timing of an ANDA filing remains constrained by the five-year NCE exclusivity period.
Potential challengers would include large generic manufacturers with experience in dermatology and immunology products. Likely commercial candidates include Teva, Sandoz, Viatris, Sun Pharma, Lupin, Dr. Reddy’s, and Zydus, although a specific company should not be treated as a Sotyktu challenger without a public Paragraph IV notice or court filing.
A first Paragraph IV filer could receive 180-day exclusivity if it satisfies statutory requirements and ultimately obtains approval. The commercial value of that position would depend on whether the core compound patents survive litigation.
What is the Paragraph IV and litigation risk?
The principal litigation scenario is a Hatch-Waxman action filed after an ANDA applicant sends a Paragraph IV notice to Bristol Myers Squibb. A timely lawsuit could trigger a 30-month stay of ANDA approval, subject to statutory exceptions and court developments.[6]
The litigation questions would likely include:
- Whether the asserted patent claims cover deucravacitinib.
- Whether the claims are invalid for anticipation or obviousness.
- Whether the patent specification adequately supports the claimed compound or use.
- Whether the generic applicant’s formulation infringes.
- Whether a narrow psoriasis indication can be carved out of the generic label.
Because Sotyktu is an oral small molecule, its generic risk is structurally higher than the risk for a complex biologic. The product does not benefit from biosimilar interchangeability barriers. Once patents and NCE exclusivity expire, an ANDA-approved generic could be substituted under state pharmacy laws, subject to local rules.
Does Sotyktu face biosimilar risk?
Sotyktu does not face biosimilar competition because it is a chemically synthesized small molecule rather than a biologic. Its relevant post-exclusivity threat is generic competition under the abbreviated new drug application pathway.
This distinction matters commercially:
- Generic manufacturers can rely on bioequivalence rather than repeating a full clinical development program.
- FDA approval can be obtained at substantially lower cost than biosimilar development.
- Pharmacy substitution can accelerate erosion after launch.
- A single generic entrant can reduce net pricing before multiple entrants appear.
The absence of biosimilar risk does not make Sotyktu safer from competition. It generally makes the eventual erosion event more concentrated and potentially faster.
What expansion opportunities could increase Sotyktu sales?
The largest value driver is indication expansion.
Psoriatic arthritis
Psoriatic arthritis offers a natural extension because it shares disease biology with psoriasis and is treated by many of the same specialists. Approval would expand use into joint disease and could increase prescribing by rheumatologists.
Systemic lupus erythematosus
TYK2 signaling has relevance to interferon-driven autoimmune disease. A successful lupus program would materially increase the addressable population, but the clinical and regulatory risk is higher than in psoriasis. Lupus trials are difficult because of heterogeneous disease biology, endpoint variability, background therapy, and placebo response.
Inflammatory bowel disease
TYK2 pathways may have relevance in ulcerative colitis and Crohn’s disease. Competition would be intense because IL-23 inhibitors, JAK inhibitors, anti-TNF products, and other advanced therapies already occupy these markets.
The probability-adjusted value of these programs is lower than the psoriasis base business until late-stage clinical data and regulatory filings establish efficacy.
How does deucravacitinib compare with other oral immunology drugs?
| Attribute |
Sotyktu |
Otezla |
JAK inhibitors |
| Mechanism |
Selective TYK2 |
PDE4 |
Broad JAK inhibition |
| Route |
Oral |
Oral |
Oral |
| Psoriasis efficacy |
High |
Moderate |
Product- and indication-dependent |
| Broad JAK safety warnings |
No class boxed warning in psoriasis label |
Different tolerability profile |
Major class warnings for several products |
| Direct biologic alternative |
Yes |
Limited |
Depends on indication |
| Generic timing |
Protected into the 2030s by patent estate, subject to validity |
Earlier generic exposure |
Varies by product |
| Expansion potential |
PsA, lupus, IBD |
More limited |
Broad but safety-constrained |
Sotyktu’s strategic position is strongest when physicians want biologic-level efficacy without injections and do not want the broader safety profile associated with traditional JAK inhibitors.
What generic launch scenarios exist for Sotyktu?
Three scenarios are commercially relevant.
Delayed generic entry
If the core patents survive litigation, generic entry could remain blocked until the principal patent expiration date or a negotiated settlement date. This scenario preserves pricing and allows Bristol Myers Squibb to maximize indication expansion.
Early negotiated entry
Bristol Myers Squibb could settle a Paragraph IV dispute by permitting a generic launch before patent expiration. The settlement could include a fixed entry date, authorized generic provisions, or restrictions on launch conditions. No public settlement had materially changed the Sotyktu outlook as of June 2024.
Patent invalidation or non-infringement
If a court invalidates or limits the core patents, multiple ANDA applicants could enter after NCE exclusivity ends. This would produce a sharper revenue decline and reduce the value of late-stage indication expansion.
How strong is the commercial outlook for deucravacitinib?
Sotyktu has a credible path to blockbuster status, but the outcome depends on expansion beyond psoriasis. Its current commercial strengths are oral administration, differentiated TYK2 selectivity, strong efficacy, and a long expected period before generic entry.
The main risks are payer controls, established biologic franchises, safety findings during broader use, slower physician switching, and failure in larger autoimmune indications. The product’s 2023 revenue base was still small relative to Bristol Myers Squibb’s largest medicines, but early growth indicates meaningful uptake.
Key Takeaways
- Deucravacitinib is the active ingredient in Bristol Myers Squibb’s Sotyktu.
- FDA approval occurred on September 9, 2022, for moderate-to-severe plaque psoriasis.
- Sotyktu generated approximately $250 million in 2023 revenue and about $111 million in first-quarter 2024 revenue.
- Five-year U.S. NCE exclusivity generally extends through September 2027.
- Core patent protection is expected to extend into the 2030s, subject to Orange Book listings, patent-term adjustment, and litigation outcomes.
- Sotyktu faces generic rather than biosimilar risk.
- Psoriatic arthritis, lupus, and inflammatory bowel disease are the main expansion opportunities.
- The commercial asset could exceed $4 billion in peak sales if it gains approvals in multiple immune-mediated diseases.
- The principal near-term risks are payer access, competition from IL-23 and IL-17 biologics, and slower-than-expected indication expansion.
FAQs About Deucravacitinib Market and Exclusivity
What was Sotyktu revenue in 2023?
Bristol Myers Squibb reported approximately $250 million in worldwide Sotyktu revenue for 2023.[2]
Is deucravacitinib a biologic?
No. Deucravacitinib is an orally administered small-molecule TYK2 inhibitor. It is exposed to generic competition rather than biosimilar competition.
When can a generic Sotyktu application be filed?
A Paragraph IV ANDA filing could generally occur after four years from the FDA approval date, around September 2026, while approval remains constrained by five-year NCE exclusivity and listed patents.
Does Sotyktu have a boxed warning?
The U.S. prescribing information did not contain a boxed warning as of June 2024. The label includes warnings and precautions concerning infections, tuberculosis, malignancy, rhabdomyolysis, and hypersensitivity.[1]
What would most increase deucravacitinib’s valuation?
Approval in psoriatic arthritis would provide the most direct commercial expansion. Successful development in systemic lupus erythematosus or inflammatory bowel disease would create larger additional opportunities but carries greater clinical risk.
References
- U.S. Food and Drug Administration. (2024). Sotyktu (deucravacitinib) prescribing information.
- Bristol-Myers Squibb Company. (2024). 2023 annual report.
- Bristol-Myers Squibb Company. (2024). First-quarter 2024 results and investor materials.
- U.S. Food and Drug Administration. (2023). New chemical entity exclusivity and abbreviated new drug applications.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and ANDA patent certification procedures.
